XML 114 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Segment, Geographic and Other Revenue Information (Tables)
 9 Months Ended
Sep. 29, 2019
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Three Months Ended
 
 
Revenues
 
Earnings(a)
(MILLIONS OF DOLLARS)
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

Reportable Segments:
 
 
 
 
 
 
 
 
Biopharma
 
$
10,108

 
$
9,422

 
$
6,503

 
$
6,206

Upjohn
 
2,195

 
3,036

 
1,353

 
2,051

Total reportable segments
 
12,303

 
12,458

 
7,856

 
8,257

Other business activities
 
—

 
—

 
(1,443
)
 
(1,298
)
Reconciling Items:
 
 
 
 
 
 

 
 

Corporate and other unallocated
 
377

 
839

 
(1,431
)
 
(1,658
)
Purchase accounting adjustments
 
—

 
—

 
(1,141
)
 
(1,309
)
Acquisition-related costs
 
—

 
—

 
(300
)
 
(112
)
Certain significant items(b)
 
—

 
—

 
7,187

 
298

 
 
$
12,680

 
$
13,298

 
$
10,727

 
$
4,177

 
 
 
Nine Months Ended
 
 
Revenues
 
Earnings(a)
(MILLIONS OF DOLLARS)
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

Reportable Segments:
 
 
 
 
 
 
 
 
Biopharma
 
$
28,887

 
$
27,737

 
$
18,484

 
$
17,987

Upjohn
 
8,077

 
9,302

 
5,577

 
6,442

Total reportable segments
 
36,964

 
37,040

 
24,062

 
24,428

Other business activities
 
—

 
—

 
(3,750
)
 
(3,605
)
Reconciling Items:
 
 
 
 
 
 
 
 
Corporate and other unallocated
 
2,098

 
2,631

 
(4,108
)
 
(4,558
)
Purchase accounting adjustments
 
—

 
—

 
(3,357
)
 
(3,665
)
Acquisition-related costs
 
—

 
—

 
(152
)
 
(221
)
Certain significant items(b)
 
—

 
—

 
6,495

 
452

 
 
$
39,062

 
$
39,670

 
$
19,190

 
$
12,831

(a) 
Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018, and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4.
(b) 
Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million, (ii) charges for certain legal matters of $63 million, (iii) charges for business and legal entity alignment of $89 million, (iv) net gains recognized during the period on investments in equity securities of $3 million, (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million, which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales, primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4.
For Earnings in the third quarter of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million, (ii) net charges for certain legal matters of $37 million, (iii) charges for business and legal entity alignment of $1 million, (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4.
For Earnings in the first nine months of 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million, (ii) charges for certain legal matters of $72 million, (iii) certain asset impairment charges of $149 million, (iv) charges for business and legal entity alignment of $353 million, (v) net gains recognized during the period on investments in equity securities of $139 million, (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion, (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million, which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales, primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4.
For Earnings in the first nine months of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million, (ii) net credits for certain legal matters of $70 million, (iii) certain asset impairment charges of $31 million, (iv) charges for business and legal entity alignment of $5 million, (v) net gains recognized during the period on investments in equity securities of $460 million, (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Three Months Ended
 
 
Revenues
 
Earnings(a)
(MILLIONS OF DOLLARS)
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

Reportable Segments:
 
 
 
 
 
 
 
 
Biopharma
 
$
10,108

 
$
9,422

 
$
6,503

 
$
6,206

Upjohn
 
2,195

 
3,036

 
1,353

 
2,051

Total reportable segments
 
12,303

 
12,458

 
7,856

 
8,257

Other business activities
 
—

 
—

 
(1,443
)
 
(1,298
)
Reconciling Items:
 
 
 
 
 
 

 
 

Corporate and other unallocated
 
377

 
839

 
(1,431
)
 
(1,658
)
Purchase accounting adjustments
 
—

 
—

 
(1,141
)
 
(1,309
)
Acquisition-related costs
 
—

 
—

 
(300
)
 
(112
)
Certain significant items(b)
 
—

 
—

 
7,187

 
298

 
 
$
12,680

 
$
13,298

 
$
10,727

 
$
4,177

 
 
 
Nine Months Ended
 
 
Revenues
 
Earnings(a)
(MILLIONS OF DOLLARS)
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

Reportable Segments:
 
 
 
 
 
 
 
 
Biopharma
 
$
28,887

 
$
27,737

 
$
18,484

 
$
17,987

Upjohn
 
8,077

 
9,302

 
5,577

 
6,442

Total reportable segments
 
36,964

 
37,040

 
24,062

 
24,428

Other business activities
 
—

 
—

 
(3,750
)
 
(3,605
)
Reconciling Items:
 
 
 
 
 
 
 
 
Corporate and other unallocated
 
2,098

 
2,631

 
(4,108
)
 
(4,558
)
Purchase accounting adjustments
 
—

 
—

 
(3,357
)
 
(3,665
)
Acquisition-related costs
 
—

 
—

 
(152
)
 
(221
)
Certain significant items(b)
 
—

 
—

 
6,495

 
452

 
 
$
39,062

 
$
39,670

 
$
19,190

 
$
12,831

(a) 
Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018, and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4.
(b) 
Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $110 million, (ii) charges for certain legal matters of $63 million, (iii) charges for business and legal entity alignment of $89 million, (iv) net gains recognized during the period on investments in equity securities of $3 million, (v) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion and (vi) other charges of $641 million, which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales, primarily for inventory manufactured for expected future sale and charges of $161 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4.
For Earnings in the third quarter of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $35 million, (ii) net charges for certain legal matters of $37 million, (iii) charges for business and legal entity alignment of $1 million, (iv) net gains recognized during the period on investments in equity securities of $85 million and (v) other income of $286 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 3 and Note 4.
For Earnings in the first nine months of 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $280 million, (ii) charges for certain legal matters of $72 million, (iii) certain asset impairment charges of $149 million, (iv) charges for business and legal entity alignment of $353 million, (v) net gains recognized during the period on investments in equity securities of $139 million, (vi) a pre-tax gain associated with the completion of the GSK Consumer Healthcare joint venture transaction of $8.1 billion, (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $738 million, which includes, among other things, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $127 million charge for rivipansel in Cost of sales, primarily for inventory manufactured for expected future sale and charges of $223 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2B, Note 3 and Note 4.
For Earnings in the first nine months of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million, (ii) net credits for certain legal matters of $70 million, (iii) certain asset impairment charges of $31 million, (iv) charges for business and legal entity alignment of $5 million, (v) net gains recognized during the period on investments in equity securities of $460 million, (vi) net losses on early retirement of debt of $3 million and (vii) other income of $89 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 3 and Note 4.
Schedule of Revenues by Geographic Region
The following table provides revenues by geographic area:
 
 
Three Months Ended

Nine Months Ended
(MILLIONS OF DOLLARS)
 
September 29,
2019

 
September 30,
2018

 
%
Change


September 29,
2019


September 30,
2018


%
Change

U.S.
 
$
5,850

 
$
6,361

 
(8
)

$
18,360


$
18,861


(3
)
Developed Europe(a)
 
2,135

 
2,231

 
(4
)

6,450


6,657


(3
)
Developed Rest of World(b)
 
1,585

 
1,640

 
(3
)

4,758


4,795


(1
)
Emerging Markets(c)
 
3,110

 
3,066

 
1


9,493


9,358


1

Revenues
 
$
12,680

 
$
13,298

 
(5
)

$
39,062


$
39,670


(2
)
(a) 
Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the third quarter of 2019 and $1.8 billion in the third quarter of 2018, and were $5.2 billion in the first nine months of 2019 and $5.3 billion in the first nine months of 2018.
(b) 
Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c) 
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey.
Schedule of Significant Product Revenues
The following table provides detailed revenue information:
(MILLIONS OF DOLLARS)
 
 
 
Three Months Ended
 
Nine Months Ended
PRODUCT
 
PRIMARY INDICATIONS OR CLASS
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

TOTAL REVENUES
 
 
 
$
12,680

 
$
13,298

 
$
39,062

 
$
39,670

PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)(a)
 
$
10,108

 
$
9,422

 
$
28,887

 
$
27,737

Internal Medicine(b)
 
 
 
$
2,207

 
$
2,182

 
$
6,754

 
$
6,529

Eliquis alliance revenues and direct sales
 
Atrial fibrillation, deep vein thrombosis, pulmonary embolism
 
1,025

 
870

 
3,121

 
2,524

Chantix/Champix
 
An aid to smoking cessation treatment in adults 18 years of age or older
 
276

 
261

 
825

 
789

Premarin family
 
Symptoms of menopause
 
182

 
204

 
542

 
605

BMP2
 
Development of bone and cartilage
 
66

 
54

 
212

 
206

Toviaz
 
Overactive bladder
 
61

 
67

 
186

 
197

All other Internal Medicine
 
Various
 
597

 
727

 
1,867

 
2,208

Oncology(c)
 
 
 
$
2,350

 
$
1,840

 
$
6,547

 
$
5,487

Ibrance
 
Advanced breast cancer
 
1,283

 
1,025

 
3,677

 
2,985

Sutent
 
Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor
 
224

 
248

 
704

 
785

Xtandi alliance revenues
 
Castration-resistant prostate cancer
 
225

 
180

 
594

 
510

Xalkori
 
ALK-positive and ROS1-positive advanced NSCLC
 
130

 
127

 
385

 
417

Inlyta
 
Advanced RCC
 
139

 
71

 
316

 
226

Bosulif
 
Philadelphia chromosome–positive chronic myelogenous leukemia
 
90

 
69

 
267

 
206

Retacrit(j)
 
Anemia
 
64

 
19

 
147

 
55

All other Oncology
 
Various
 
194

 
101

 
456

 
302

Hospital(d)
 
 
 
$
1,917

 
$
1,841

 
$
5,717

 
$
5,944

Sulperazon
 
Treatment of infections
 
163

 
145

 
505

 
464

Medrol(e)
 
Steroid anti-inflammatory
 
109

 
110

 
348

 
369

Vfend
 
Fungal infections
 
87

 
87

 
265

 
294

Zithromax(e)
 
Bacterial infections
 
77

 
61

 
254

 
243

EpiPen
 
Epinephrine injection used in treatment of life-threatening allergic reactions
 
92

 
68

 
238

 
215

Zyvox
 
Bacterial infections
 
61

 
50

 
195

 
184

Fragmin
 
Slows blood clotting
 
62

 
76

 
185

 
221

Zosyn/Tazocin
 
Antibiotic
 
49

 
56

 
153

 
176

Tygacil
 
Tetracycline class antibiotic
 
50

 
60

 
146

 
186

Pfizer CentreOne(f)
 
Various
 
176

 
159

 
556

 
539

All other Anti-infectives
 
Various
 
335

 
300

 
961

 
929

All other Hospital(d)
 
Various
 
656

 
669

 
1,910

 
2,124

Vaccines
 
 
 
$
1,808

 
$
1,845

 
$
4,795

 
$
4,708

Prevnar 13/Prevenar 13
 
Pneumococcal disease
 
1,603

 
1,660

 
4,268

 
4,290

FSME/IMMUN-TicoVac
 
Tick-borne encephalitis disease
 
64

 
57

 
197

 
162

Nimenrix
 
Meningococcal disease
 
52

 
46

 
159

 
95

Trumenba
 
Meningococcal disease
 
73

 
61

 
117

 
95

All other Vaccines
 
Various
 
16

 
21

 
54

 
65

Inflammation & Immunology (I&I)(g)
 
$
1,226

 
$
1,184

 
$
3,482

 
$
3,419

Xeljanz
 
RA, PsA, UC
 
599

 
432

 
1,634

 
1,221

Enbrel (Outside the U.S. and Canada)
 
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
 
415

 
531

 
1,285

 
1,589

Inflectra/Remsima(g), (j)
 
Inflammatory diseases
 
155

 
166

 
446

 
469

Eucrisa
 
Mild-to-moderate atopic dermatitis (eczema)
 
43

 
40

 
92

 
104

All other I&I
 
Various
 
15

 
14

 
24

 
36


(MILLIONS OF DOLLARS)
 
 
 
Three Months Ended
 
Nine Months Ended
PRODUCT
 
PRIMARY INDICATIONS OR CLASS
 
September 29,
2019

 
September 30,
2018

 
September 29,
2019

 
September 30,
2018

Rare Disease
 
 
 
$
601

 
$
531

 
$
1,592

 
$
1,651

BeneFIX
 
Hemophilia
 
125

 
132

 
372

 
420

Genotropin
 
Replacement of human growth hormone
 
124

 
143

 
357

 
416

Refacto AF/Xyntha
 
Hemophilia
 
104

 
117

 
319

 
388

Vyndaqel
 
ATTR-Cardiomyopathy and Polyneuropathy
 
156

 
37

 
259

 
108

Somavert
 
Acromegaly
 
64

 
64

 
192

 
195

All other Rare Disease
 
Various
 
28

 
38

 
94

 
123

UPJOHN(b), (h)
 
 
 
$
2,195

 
$
3,036

 
$
8,077

 
$
9,302

Lyrica
 
Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury
 
527

 
1,213

 
2,888

 
3,649

Lipitor
 
Reduction of LDL cholesterol
 
476

 
507

 
1,506

 
1,539

Norvasc
 
Hypertension
 
219

 
248

 
735

 
777

Celebrex
 
Arthritis pain and inflammation, acute pain
 
179

 
188

 
526

 
494

Viagra
 
Erectile dysfunction
 
120

 
137

 
379

 
509

Effexor
 
Depression and certain anxiety disorders
 
80

 
78

 
242

 
228

Zoloft
 
Depression and certain anxiety disorders
 
74

 
72

 
217

 
223

Xalatan/Xalacom
 
Glaucoma and ocular hypertension
 
68

 
76

 
201

 
233

Xanax
 
Anxiety disorders
 
50

 
52

 
147

 
163

Revatio
 
Pulmonary arterial hypertension
 
24

 
53

 
122

 
163

All other Upjohn
 
Various
 
379

 
411

 
1,114

 
1,325

CONSUMER HEALTHCARE BUSINESS(i)
 
$
377

 
$
839

 
$
2,098

 
$
2,631

 
 
 
 
 
 
 
 
 
 
 
Total Alliance revenues
 
Various
 
$
1,141

 
$
977

 
$
3,418

 
$
2,820

Total Biosimilars(j)
 
Various
 
$
236

 
$
197

 
$
632

 
$
558

Total Sterile Injectable Pharmaceuticals(k)
 
$
1,248

 
$
1,239

 
$
3,703

 
$
3,928


(a) 
The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Disease. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne(f).
(b) 
We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation.
(c) 
We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation.
(d) 
Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne(f). All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
(e) 
2018 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.
(f) 
Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(g) 
We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation.
(h) 
Pfizer’s Upjohn business encompasses primarily off-patent branded and generic medicines that includes a portfolio of 20 globally recognized solid oral dose brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone.
(i) 
On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 1A and Note 2B.
(j) 
Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
(k) 
Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.